Entheon Biomedical Corp.
ENTBF
$0.069
-$0.0114-14.18%
OTC PK
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -34.71% | 79.83% | 13.32% | -32.18% | -36.85% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -34.71% | 79.83% | 13.32% | -32.18% | -36.85% |
| Operating Income | 34.71% | -79.83% | -13.32% | 32.18% | -232.89% |
| Income Before Tax | 31.84% | -82.59% | -12.99% | 33.71% | -161.89% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.84% | -82.59% | -12.99% | 33.71% | -161.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.84% | -82.59% | -12.99% | 33.71% | -161.89% |
| EBIT | 34.71% | -79.83% | -13.32% | 32.18% | -232.89% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 64.21% | 9.57% | 24.18% | 55.83% | -111.11% |
| Normalized Basic EPS | 64.41% | 10.17% | 36.76% | 54.17% | -145.83% |
| EPS Diluted | 64.21% | 9.57% | 24.18% | 64.67% | -28.38% |
| Normalized Diluted EPS | 64.41% | 10.17% | 36.76% | 54.17% | -145.83% |
| Average Basic Shares Outstanding | 89.33% | 103.52% | 49.79% | 49.92% | 23.88% |
| Average Diluted Shares Outstanding | 89.33% | 103.52% | 49.79% | 49.92% | 23.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |